RAPT Therapeutics, Inc.
RAPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $64 | $953 | $644 | $1,006 |
| - Cash | $170 | $47 | $39 | $24 |
| + Debt | $4 | $7 | $9 | $0 |
| Enterprise Value | -$101 | $912 | $614 | $982 |
| Revenue | $0 | $0 | $2 | $4 |
| % Growth | – | -100% | -60% | – |
| Gross Profit | $0 | $0 | $2 | $4 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$135 | -$126 | -$85 | -$68 |
| % Margin | – | – | -5,550% | -1,789% |
| Net Income | -$130 | -$117 | -$84 | -$69 |
| % Margin | – | – | -5,490.4% | -1,814.9% |
| EPS Diluted | -25.488 | -24.372 | -20.611 | -20.213 |
| % Growth | -4.6% | -18.2% | -2% | – |
| Operating Cash Flow | -$83 | -$97 | -$71 | -$61 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$1 |
| Free Cash Flow | -$83 | -$98 | -$72 | -$62 |